## Most Common Opportunistic Infection with Methotrexate **Key Point:** Pneumocystis jirovecii pneumonia (PJP) is the most commonly reported opportunistic infection in patients receiving methotrexate for rheumatoid arthritis, as documented in pharmacovigilance databases and clinical literature worldwide. ### Why PJP Is Most Common with Methotrexate **High-Yield:** Methotrexate impairs cell-mediated immunity through: 1. Inhibition of dihydrofolate reductase → reduced folate-dependent nucleotide synthesis 2. Suppression of T-lymphocyte (especially CD4+) proliferation 3. Impaired macrophage activation and cytokine production 4. This specifically weakens the Th1/CD4+ T-cell response that is critical for containing *Pneumocystis jirovecii* ### Epidemiology and Clinical Significance | Aspect | Details | |--------|---------| | **Incidence** | PJP risk is significantly elevated in MTX-treated RA patients vs. general population | | **CD4 threshold** | Unlike HIV, PJP in MTX users can occur even with CD4 counts >200 cells/µL | | **Mortality** | Case fatality rate 30–50% if untreated; high even with treatment in elderly RA patients | | **Prophylaxis** | Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended in high-risk patients | | **Screening** | No reliable pre-treatment screening test; clinical vigilance is key | ### Clinical Presentation **Clinical Pearl:** PJP in methotrexate-treated RA patients may present atypically: - Subacute onset of dyspnea, dry cough, and low-grade fever - Bilateral interstitial infiltrates on chest X-ray ("ground-glass" pattern on CT) - Hypoxia disproportionate to clinical appearance - LDH often elevated; β-D-glucan positive - BAL with Gomori methenamine silver (GMS) stain confirms diagnosis ### Comparison with Other Opportunistic Infections | Infection | Relative Risk with MTX | Notes | |-----------|------------------------|-------| | **PJP** | High (most common) | CD4-independent risk; prophylaxis recommended | | **Tuberculosis** | Moderate (region-dependent) | Highest in endemic areas; screening mandatory | | **Invasive Aspergillosis** | Low–Moderate | More common with high-dose steroids | | **CMV Retinitis** | Low | Primarily in severely immunocompromised (HIV, transplant) | **Mnemonic — PJP with MTX:** **P**neumocystis **J**irovecii **P**neumonia — think "**P**lease **J**ust **P**rophylax" with TMP-SMX in high-risk methotrexate users. ### Management Strategy - **Prophylaxis:** TMP-SMX (co-trimoxazole) one double-strength tablet three times weekly is the standard prophylaxis for PJP in high-risk MTX patients - **Treatment:** High-dose TMP-SMX IV/oral for 21 days; adjunctive corticosteroids if PaO₂ <70 mmHg - **MTX management:** Withhold methotrexate during active PJP infection **High-Yield (KD Tripathi / Harrison):** Among all immunosuppressants used in rheumatology, methotrexate is specifically associated with PJP as the most frequently documented opportunistic infection in clinical series and adverse drug reaction databases. TB, while important in endemic regions, is more characteristically linked to TNF-α inhibitors (biologics) due to granuloma disruption, not methotrexate per se.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.